Cargando…
Adenosine signaling: Optimal target for gastric cancer immunotherapy
Gastric cancer (GC) is one of the most common malignancy and leading cause of cancer-related deaths worldwide. Due to asymptomatic or only nonspecific early symptoms, GC patients are usually in the advanced stage at first diagnosis and miss the best opportunity of treatment. Immunotherapies, especia...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523428/ https://www.ncbi.nlm.nih.gov/pubmed/36189223 http://dx.doi.org/10.3389/fimmu.2022.1027838 |
_version_ | 1784800286289690624 |
---|---|
author | Wang, Junqing Du, Linyong Chen, Xiangjian |
author_facet | Wang, Junqing Du, Linyong Chen, Xiangjian |
author_sort | Wang, Junqing |
collection | PubMed |
description | Gastric cancer (GC) is one of the most common malignancy and leading cause of cancer-related deaths worldwide. Due to asymptomatic or only nonspecific early symptoms, GC patients are usually in the advanced stage at first diagnosis and miss the best opportunity of treatment. Immunotherapies, especially immune checkpoint inhibitors (ICIs), have dramatically changed the landscape of available treatment options for advanced-stage cancer patients. However, with regards to existing ICIs, the clinical benefit of monotherapy for advanced gastric cancer (AGC) is quite limited. Therefore, it is urgent to explore an optimal target for the treatment of GC. In this review, we summarize the expression profiles and prognostic value of 20 common immune checkpoint-related genes in GC from Gene Expression Profiling Interactive Analysis (GEPIA) database, and then find that the adenosinergic pathway plays an indispensable role in the occurrence and development of GC. Moreover, we discuss the pathophysiological function of adenosinergic pathway in cancers. The accumulation of extracellular adenosine inhibits the normal function of immune effector cells and facilitate the effect of immunosuppressive cells to foster GC cells proliferation and migration. Finally, we provide insights into potential clinical application of adenosinergic-targeting therapies for GC patients. |
format | Online Article Text |
id | pubmed-9523428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95234282022-10-01 Adenosine signaling: Optimal target for gastric cancer immunotherapy Wang, Junqing Du, Linyong Chen, Xiangjian Front Immunol Immunology Gastric cancer (GC) is one of the most common malignancy and leading cause of cancer-related deaths worldwide. Due to asymptomatic or only nonspecific early symptoms, GC patients are usually in the advanced stage at first diagnosis and miss the best opportunity of treatment. Immunotherapies, especially immune checkpoint inhibitors (ICIs), have dramatically changed the landscape of available treatment options for advanced-stage cancer patients. However, with regards to existing ICIs, the clinical benefit of monotherapy for advanced gastric cancer (AGC) is quite limited. Therefore, it is urgent to explore an optimal target for the treatment of GC. In this review, we summarize the expression profiles and prognostic value of 20 common immune checkpoint-related genes in GC from Gene Expression Profiling Interactive Analysis (GEPIA) database, and then find that the adenosinergic pathway plays an indispensable role in the occurrence and development of GC. Moreover, we discuss the pathophysiological function of adenosinergic pathway in cancers. The accumulation of extracellular adenosine inhibits the normal function of immune effector cells and facilitate the effect of immunosuppressive cells to foster GC cells proliferation and migration. Finally, we provide insights into potential clinical application of adenosinergic-targeting therapies for GC patients. Frontiers Media S.A. 2022-09-16 /pmc/articles/PMC9523428/ /pubmed/36189223 http://dx.doi.org/10.3389/fimmu.2022.1027838 Text en Copyright © 2022 Wang, Du and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Junqing Du, Linyong Chen, Xiangjian Adenosine signaling: Optimal target for gastric cancer immunotherapy |
title | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
title_full | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
title_fullStr | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
title_full_unstemmed | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
title_short | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
title_sort | adenosine signaling: optimal target for gastric cancer immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523428/ https://www.ncbi.nlm.nih.gov/pubmed/36189223 http://dx.doi.org/10.3389/fimmu.2022.1027838 |
work_keys_str_mv | AT wangjunqing adenosinesignalingoptimaltargetforgastriccancerimmunotherapy AT dulinyong adenosinesignalingoptimaltargetforgastriccancerimmunotherapy AT chenxiangjian adenosinesignalingoptimaltargetforgastriccancerimmunotherapy |